PhRMA
JUNE 14, 2023
The 340B Drug Pricing Program has grown yet again , exceeding $100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost. Recent data from IQVIA shows 340B grew 12.2% year-over-year in 2022, continuing a trend in which 340B sales have almost doubled since 2018, outpacing growth of the total U.S. drug market.
Drug Topics
JUNE 14, 2023
Drug Topics spoke to father and son pharmacist duo Grant and Austin Brown for a conversation about the evolution of the practice, the importance of holding elected officials accountable, and more.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JUNE 13, 2023
Police drug busts are strongly associated with a large and sudden spike in overdose deaths, according to a new study. In the week following a major opioid bust, fatal overdoses in the same neighborhood in Indianapolis doubled, the analysis showed. Calls to 911 and the use of naloxone , the overdose-reversal medication, also spiked.
Fierce Pharma
JUNE 12, 2023
Two years after the initial COVID-19 vaccine push swept across the globe, Pfizer’s COVID-19 vaccine partner BioNTech is heading to court in its home country of Germany to defend itself against alle | The drugmaker will defend itself against claims from a German healthcare worker who sued the company for at least 150,000 euros ($161,500). The plaintiff alleges she suffered bodily harm resulting from Pfizer and BioNTech's Comirnaty vaccine.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PhRMA
JUNE 16, 2023
This June marks Lesbian, Gay, Bisexual, Transgender and Queer (LGBTQ+) Pride Month. At PhRMA, we’re proud to celebrate the diversity and inclusion of our LGBTQ+ colleagues and the patients our companies aim to help. As an industry driven by science, we believe diversity in the lab drives greater collaboration, scientific advancement and groundbreaking medicines impacting the lives of patients.
Drug Topics
JUNE 15, 2023
G2Retro, developed by investigators from Ohio State University, can produce hundreds of new reaction predictions in just a few minutes.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Pharma
JUNE 12, 2023
Bayer recently laid out its ambition | Bayer recently laid out its ambition to achieve $10 billion in sales from its oncology business by 2030 and become a top 10 cancer drug player. To get there, the company is looking outside for a “midsize acquisition,” Bayer’s oncology chief Christine Roth said.
STAT
JUNE 13, 2023
CHICAGO — The American Medical Association on Tuesday strongly criticized the body mass index , urging doctors to de-emphasize its use in assessing health and obesity and acknowledging that the measurement has been used for “racist exclusion” and has caused “historical harm.” The AMA, one of the largest medical groups in the U.S., voted to adopt this policy during its annual meeting here.
Drug Topics
JUNE 15, 2023
The iLet Bionic Pancreas combines data from the Dexcom G6 CGM with different algorithms to deliver insulin throughout the day.
Pharmacy Times
JUNE 16, 2023
Patient education and counseling play a critical role in preventing C. difficile recurrence, and pharmacists are uniquely positioned to provide treatment recommendations, educate patients and health care providers, optimize transitions of care, and reduce the risk of recurrent CDI.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Pharma
JUNE 16, 2023
Merck’s cancer star Keytruda could be on its way to an updated label in HER2-positive stomach cancer after showing it can stave off tumor progression in a combination study. | After scoring accelerated approval to treat HER2-positive stomach cancer in 2021, the drug has now shown it can stave off tumor progression in patients with PD-L1 positive tumors.
STAT
JUNE 13, 2023
Adolescents who seek treatment for opioid addiction at an inpatient facility are more likely to be offered horseback riding than given full access to a common, highly effective addiction medication. According to a new research paper, just one out of every eight residential treatment facilities open to patients ages 16 or 17 offers full access to buprenorphine.
Drug Topics
JUNE 12, 2023
A look at how the genetics-based research field can become more fully integrated in all areas of health care going forward.
Pharmacy Times
JUNE 16, 2023
Imposing the FDA on-label/off-label framework on administratively defined "children" resulted in a regulatory demand for pediatric studies that had no basis in clinical medicine, with the exception of the small group of preterm newborns.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
JUNE 16, 2023
In the battle for superiority in the field of next-gen diabetes and obesity treatments, Novo Nordisk holds the lead as the developer of the metabolism-regulating treatment semaglutide. | In the battle for diabetes and obesity superiority, Novo Nordisk holds a head start as the original developer of the metabolism-regulating treatment semaglutide. But Eli Lilly is quickly gaining ground and is primed to become the market leader with its GLP-1 treatment Mounjaro, according to GlobalData.
Fierce Healthcare
JUNE 14, 2023
Over 90% of respondents to a recent U.S. News and World Report survey said their goal is to age in place. | More than 90% of respondents to a recent U.S. News and World Report survey said their goal is to age in place. A whopping 88% also reported that assistive or health-related technologies have improved their quality of life.
Drug Topics
JUNE 12, 2023
Over 90% of survey respondents said they believed emergency response simulation training should be required annually.
Pharmacy Times
JUNE 16, 2023
Heidi Finnes, PharmD, BCOP, FHOPA, director of clinical ambulatory pharmacy practice at Mayo Clinic, discussed updates in melanoma and the use of immunotherapies and targeted therapies.
Fierce Pharma
JUNE 16, 2023
Less than a month after AbbVie and Genmab won FDA approval for Epkinly, Roche has crossed the finish line with its bispecific answer to large B-cell lymphoma. | Less than a month after AbbVie and Genmab won FDA approval for Epkinly, Roche has crossed the finish line with its bispecific answer to large B-cell lymphoma, though with a narrower label.
Fierce Healthcare
JUNE 16, 2023
With the release of ChatGPT, what had long been science fiction became a reality, leaving healthcare wondering where medicine meets machine. | This week, Stanford Medicine and Stanford Institute for Human-Centered Artificial Intelligence (HAI) launched Responsible AI for Safe and Equitable Health (RAISE-Health) with the goal of addressing critical ethical and safety issues regarding the technology.
Drug Topics
JUNE 15, 2023
Meet this year’s Pharmacy of the Year nominees and preview some of the sessions available at this year’s meeting.
Pharmacy Times
JUNE 16, 2023
VALOR HCM is the second study to show that mavacamten can significantly reduce symptoms of obstructive hypertrophic cardiomyopathy, which includes left ventricular outflow tract.
Fierce Pharma
JUNE 14, 2023
Sanofi is jumping on the artificial intelligence boat with a new app and a pledge to become “the first pharma company powered by artificial intelligence at scale.” | Sanofi's new app, plai, provides teams with a “360° view" to aid decision-making. The platform is one step in the company's digital transformation and goal to become the "first pharma powered by AI at scale.
Fierce Healthcare
JUNE 14, 2023
Digital health companies should brace for a shake-up as COVID-era contracts inked with hospitals will soon be up for renewal, according to the results of a recent survey. | Numerous digital health contracts signed by hospitals reacting to COVID-19 are nearing their conclusion, giving many providers a chance to reevaluate their options, a recent executive survey suggests.
Drug Topics
JUNE 13, 2023
What is the state of OTC contraception, what’s next for IUDs, and why are so many transgender people denied care?
Pharmacy Times
JUNE 16, 2023
Claire Biermaas, president of Corporate Partnerships at AmerisourceBergen, discussed the Corporate Partnerships Team, which works closely with pharmacy customers to guide their processes and help execute their vision.
Fierce Pharma
JUNE 12, 2023
Another biosimilar product copying Johnson & Johnson’s top-selling drug Stelara may enter the U.S. market without a patent infringement challenge by early 2025 thanks to a new settlement. | Following a deal with Amgen, J&J has granted Alvotech and Teva a license to launch their Stelara biosimilar no later than Feb. 21, 2025.
Fierce Healthcare
JUNE 15, 2023
Retail pharmacy giant Walgreens inked another partnership to recruit participants for research as it continues to build out its clinical trials business. | Retail pharmacy giant Walgreens inked another partnership to recruit participants for research as it continues to build out its clinical trials business.
Drug Topics
JUNE 15, 2023
Novo Nordisk is the only company with FDA-approved products containing semaglutide.
Pharmacy Times
JUNE 16, 2023
Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.
STAT
JUNE 12, 2023
Brain responses to nutrients in the gut are impaired in people with obesity, and that doesn’t change even after they lose weight through changes in diet, a new study finds, adding to mounting research showing the complexity and persistence of the biological effects of obesity. Using brain imaging, researchers saw that when people without obesity received nutrients, they experienced reduced activity in areas of the brain involved in food intake, suggesting the brain is signaling to them th
Fierce Pharma
JUNE 13, 2023
Biogen has taken a step to “significantly refresh” its board of directors, departing chair Stelios Papadopoulos, Ph.D., said. | Biogen has taken a step to “significantly refresh” its board of directors, departing chair Stelios Papadopoulos, Ph.D., said. But the reported romantic relationship between a new nominee and a departing member raises questions about one appointment.
Drug Topics
JUNE 12, 2023
What stood out on Sunday and Monday at the 2023 ASHP Summer Meetings in Baltimore?
Pharmacy Times
JUNE 16, 2023
Both immunotherapies and targeted therapies are showing significant promise in these areas, offering patients new treatment options.
Expert insights. Personalized for you.
261 
Let's personalize your content